<?xml version="1.0" encoding="UTF-8"?>
<p>Among developing live attenuated mucosal vaccines, the major class of vaccines, oral vaccines, are currently being assessed in clinical studies. Oral vaccines are classified into intranasal and sublingual vaccines that are developed for the control of influenza, rotavirus, norovirus and measles viruses [
 <xref rid="B83-viruses-12-00862" ref-type="bibr">83</xref>]. Experimental LAIVs have been found to be effective in poultry [
 <xref rid="B84-viruses-12-00862" ref-type="bibr">84</xref>]. LAIVs have been administered to adults in Russia since the 1950s. Starting from 1987, LAIV administration in Russia has been implemented throughout various age groups [
 <xref rid="B85-viruses-12-00862" ref-type="bibr">85</xref>,
 <xref rid="B86-viruses-12-00862" ref-type="bibr">86</xref>]. LAIVs were licensed in the US in 2003 for use in healthy individuals aged 2–49 years, while in the EU in 2012 for normal children aged 2–17 years [
 <xref rid="B87-viruses-12-00862" ref-type="bibr">87</xref>].
</p>
